Psychedelics for depression and PTSD | Professor and cognitive neuropsychiatrist Susan Rossell, PhD

Safety Protocols

The therapeutic use of psychedelics like psilocybin and MDMA requires rigorous safety protocols due to potential risks. Susan Rossell highlights the occurrence of "bad trips," where participants may experience severe psychological distress, such as feeling trapped in a nightmare 1. These adverse reactions are not necessarily dose-dependent but may be influenced by individual physiology and psychological history. Rossell emphasizes the need for comprehensive psychotherapy to help individuals process these experiences, stating,

We need to work these things out with a lot of psychotherapy instead of doing the psychedelic psychotherapy therapy.

--- Susan Rossell

In therapeutic settings, psilocybin is used alongside psychotherapy to facilitate healing, while MDMA is noted for its ability to enhance self-compassion through an oxytocin rush 2.

   

Ethical Challenges

Ethical challenges in psychedelic research involve balancing potential benefits with safety concerns. Susan Rossell expresses concern over the Therapeutic Goods Administration's (TGA) rapid change in stance on psychedelic scheduling, influenced by lobbyists despite limited safety data 3. She argues for more rigorous research before widespread use, fearing untrained therapists could lead to negative outcomes. Rossell states,

I'm most concerned that then it becomes like the scheduling gets more stringent again.

--- Susan Rossell

The pressure to expedite these treatments without adequate data could result in setbacks, highlighting the need for careful consideration and robust safety measures 4.

   

Regulatory Debates

Regulatory debates focus on the decriminalization and controlled use of psychedelics. Susan Rossell advocates for decriminalization to ensure safety, citing the Netherlands as a model where controlled settings reduced risks 5. She acknowledges the premature nature of current research, emphasizing the need for long-term safety data before a global rollout. Rossell explains,

Until we start to do real world trials with real world long term data, we are so premature.

--- Susan Rossell

The lack of comprehensive guidelines and long-term studies raises concerns about the potential impact of bad trips and the broader application of these therapies 6.